Tags

Type your tag names separated by a space and hit enter

[Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy].
Zhonghua Jie He He Hu Xi Za Zhi 1998; 21(11):645-7ZJ

Abstract

OBJECTIVE

To assess antituberculous efficacy, patients' compliance and application perspective of fixed-dose compounds rifater/rifinah in China.

METHOD

Three hundred eight new smear positive pulmonary tuberculosis patients were randomly allocated with a ratio of 2 to 1 into treatment group (227 cases, receiving 2RIFATER/4RIFINAH regimen) and controls (81 cases, 2HRZ/4HR) for observation.

RESULT

The sputum negative conversion rates at the 2nd month in the treatment group and the controls were 91.2% and 86.4% respectively, and at the end of the chemotherapy 98.7% and 97.5%. Chest radiography showed remarkable improvement. The resolution of pulmonary lesions in the treatment group and the controls accounted for 95.2% and 93.8% respectively, with cavity closure rates of 68.6% in the treatment group and 67.9% in the controls. The drug adverse reaction rates were 8.9% in both groups, and the default rates were 4.3% and 7.8% respectively.

CONCLUSION

Fixed-dose compounds rifater/rifinah show excellent therapeutic efficacy, safety and compliance in antituberculous chemotherapy, which could be recommended for wider use in tuberculosis control in China.

Authors+Show Affiliations

Beijing Institute of Tuberculosis and Thoracic Tumor, Beijing 101149.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article
Randomized Controlled Trial

Language

chi

PubMed ID

11477887

Citation

Zhu, L, et al. "[Controlled Clinical Study On Efficacy of Fixed-dose Compounds Rifater/rifinah in Antituberculous Chemotherapy]." Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases, vol. 21, no. 11, 1998, pp. 645-7.
Zhu L, Yan B, Ma W. [Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy]. Zhonghua Jie He He Hu Xi Za Zhi. 1998;21(11):645-7.
Zhu, L., Yan, B., & Ma, W. (1998). [Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases, 21(11), pp. 645-7.
Zhu L, Yan B, Ma W. [Controlled Clinical Study On Efficacy of Fixed-dose Compounds Rifater/rifinah in Antituberculous Chemotherapy]. Zhonghua Jie He He Hu Xi Za Zhi. 1998;21(11):645-7. PubMed PMID: 11477887.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy]. AU - Zhu,L, AU - Yan,B, AU - Ma,W, PY - 2001/8/2/pubmed PY - 2001/9/21/medline PY - 2001/8/2/entrez SP - 645 EP - 7 JF - Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases JO - Zhonghua Jie He He Hu Xi Za Zhi VL - 21 IS - 11 N2 - OBJECTIVE: To assess antituberculous efficacy, patients' compliance and application perspective of fixed-dose compounds rifater/rifinah in China. METHOD: Three hundred eight new smear positive pulmonary tuberculosis patients were randomly allocated with a ratio of 2 to 1 into treatment group (227 cases, receiving 2RIFATER/4RIFINAH regimen) and controls (81 cases, 2HRZ/4HR) for observation. RESULT: The sputum negative conversion rates at the 2nd month in the treatment group and the controls were 91.2% and 86.4% respectively, and at the end of the chemotherapy 98.7% and 97.5%. Chest radiography showed remarkable improvement. The resolution of pulmonary lesions in the treatment group and the controls accounted for 95.2% and 93.8% respectively, with cavity closure rates of 68.6% in the treatment group and 67.9% in the controls. The drug adverse reaction rates were 8.9% in both groups, and the default rates were 4.3% and 7.8% respectively. CONCLUSION: Fixed-dose compounds rifater/rifinah show excellent therapeutic efficacy, safety and compliance in antituberculous chemotherapy, which could be recommended for wider use in tuberculosis control in China. SN - 1001-0939 UR - https://www.unboundmedicine.com/medline/citation/11477887/[Controlled_clinical_study_on_efficacy_of_fixed_dose_compounds_rifater/rifinah_in_antituberculous_chemotherapy]_ DB - PRIME DP - Unbound Medicine ER -